Description General description 5-Azacytidine is a chemical analog of cytidine. It functions as a hypomethylating agent. 5-Azacytidine is used to treat myelodysplastic syndrome (MDS). Chemical structure: nucleoside Application 5-Azacytidine has been used: • for cell induction • to study its effects on bovine fetal mesenchymal stem cells (bfMSC) • to study its effects on human bone marrow stromal cells (hBMSCs) • to study its effects on and DNA methyltransferase 1 (DNMT1) and Ras protein activator like 1 (RASAL1) expression • to interfere with DNA methylation and histone acetylation • to determine its effects on the conversion of control fibroblasts • for optical coherence tomography (OCT) and fluorescein angiography (FA) • for the reactivation of Sal-like protein (SALL)3 expression Packaging 1 g in poly bottle 100, 250 mg in poly bottle Biochem/physiol Actions 5-Azacytidine (Aza-CR) acts as a potential chemotherapeutic regimen for acute myelogenous leukemia. This drug has an ability to selectively increase γ-globin synthesis. Therefore, 5-azacytidine is used in treating severe β-thalassemia. Aza-CR acts as a potential bacteriostatic, antitumor and mutagenic agent. In addition, it also exhibits various biological activity such as, immunosuppressive, antimitotic, radioprotective and virostatic effects. A potent growth inhibitor and cytotoxic agent; inhibits DNA methyltransferase, an important regulatory mechanism of gene expression, gene activation and silencing. Causes DNA demethylation or hemi-demethylation, creating openings that allow transcription factors to bind to DNA and reactivate tumor suppressor genes. Features and Benefits This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm. This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more. This compound was developed by Celgene. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. Legal Information LOPAC is a registered trademark of Sigma-Aldrich Co. LLC